These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 12456201)

  • 1. Use of randomised controlled trials for producing cost-effectiveness evidence: potential impact of design choices on sample size and study duration.
    Backhouse ME
    Pharmacoeconomics; 2002; 20(15):1061-77. PubMed ID: 12456201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-utility analysis conducted alongside randomized controlled trials: are economic end points considered in sample size calculations and does it matter?
    Hollingworth W; McKell-Redwood D; Hampson L; Metcalfe C
    Clin Trials; 2013 Feb; 10(1):43-53. PubMed ID: 23231969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Power and sample size calculations for stochastic cost-effectiveness analysis.
    Briggs AH; Gray AM
    Med Decis Making; 1998; 18(2 Suppl):S81-92. PubMed ID: 9566469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of information methods to design a clinical trial in a small population to optimise a health economic utility function.
    Pearce M; Hee SW; Madan J; Posch M; Day S; Miller F; Zohar S; Stallard N
    BMC Med Res Methodol; 2018 Feb; 18(1):20. PubMed ID: 29422021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized controlled trial and economic evaluation.
    Jain S; Arora NK
    Indian J Pediatr; 2000 May; 67(5):363-8. PubMed ID: 10885210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using value of information methods to determine the optimal sample size for effectiveness trials of alcohol interventions for HIV-infected patients in East Africa.
    Li L; Uyei J; Nucifora KA; Kessler J; Stevens ER; Bryant K; Braithwaite RS
    BMC Health Serv Res; 2018 Jul; 18(1):590. PubMed ID: 30064428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report.
    Ramsey SD; Willke RJ; Glick H; Reed SD; Augustovski F; Jonsson B; Briggs A; Sullivan SD
    Value Health; 2015 Mar; 18(2):161-72. PubMed ID: 25773551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analyses of cost data in economic evaluations conducted alongside randomized controlled trials.
    Doshi JA; Glick HA; Polsky D
    Value Health; 2006; 9(5):334-40. PubMed ID: 16961551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report.
    Ramsey S; Willke R; Briggs A; Brown R; Buxton M; Chawla A; Cook J; Glick H; Liljas B; Petitti D; Reed S
    Value Health; 2005; 8(5):521-33. PubMed ID: 16176491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis and interpretation of cost data in randomised controlled trials: review of published studies.
    Barber JA; Thompson SG
    BMJ; 1998 Oct; 317(7167):1195-200. PubMed ID: 9794854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Confidence intervals for cost-effectiveness ratios: an application of Fieller's theorem.
    Willan AR; O'Brien BJ
    Health Econ; 1996; 5(4):297-305. PubMed ID: 8880166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of information methods for planning and analyzing clinical studies optimize decision making and research planning.
    Willan AR; Goeree R; Boutis K
    J Clin Epidemiol; 2012 Aug; 65(8):870-6. PubMed ID: 22609138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determining optimal sample sizes for multistage adaptive randomized clinical trials from an industry perspective using value of information methods.
    Chen MH; Willan AR
    Clin Trials; 2013 Feb; 10(1):54-62. PubMed ID: 23263520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing generalisability by location in trial-based cost-effectiveness analysis: the use of multilevel models.
    Manca A; Rice N; Sculpher MJ; Briggs AH
    Health Econ; 2005 May; 14(5):471-85. PubMed ID: 15386662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using routine data to complement and enhance the results of randomised controlled trials.
    Lewsey JD; Leyland AH; Murray GD; Boddy FA
    Health Technol Assess; 2000; 4(22):1-55. PubMed ID: 11074392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sample size and number of outcome measures of veterinary randomised controlled trials of pharmaceutical interventions funded by different sources, a cross-sectional study.
    Wareham KJ; Hyde RM; Grindlay D; Brennan ML; Dean RS
    BMC Vet Res; 2017 Oct; 13(1):295. PubMed ID: 28978314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Educational interventions to improve quality of life in people with chronic inflammatory skin diseases: systematic reviews of clinical effectiveness and cost-effectiveness.
    Pickett K; Loveman E; Kalita N; Frampton GK; Jones J
    Health Technol Assess; 2015 Oct; 19(86):1-176, v-vi. PubMed ID: 26502807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Collecting and analysing cost data for complex public health trials: reflections on practice.
    Batura N; Pulkki-Brännström AM; Agrawal P; Bagra A; Haghparast-Bidgoli H; Bozzani F; Colbourn T; Greco G; Hossain T; Sinha R; Thapa B; Skordis-Worrall J
    Glob Health Action; 2014; 7():23257. PubMed ID: 24565214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Handling missing data in patient-level cost-effectiveness analysis alongside randomised clinical trials.
    Manca A; Palmer S
    Appl Health Econ Health Policy; 2005; 4(2):65-75. PubMed ID: 16162026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.